- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06089616
En studie for å dokumentere og ytterligere beskrive langsiktig sikkerhet og effektivitet av palovaroten hos deltakere med Fibrodysplasia Ossificans Progressiva (FOP) (FOPal)
En internasjonal observasjonsregisterstudie for ytterligere å beskrive langsiktig sikkerhet og effektivitet av palovaroten hos pasienter med Fibrodysplasia Ossificans Progressiva (FOP)
The participants in this registry study will have fibrodysplasia ossificans progressiva (FOP).
FOP is an ultra-rare, severely disabling disease characterized by new bone formation in areas of the body where bone is not normally present (heterotopic ossification (HO)).
HO is often preceded by painful, recurrent episodes of soft tissue swelling (flare-ups).
This registry study will take place in countries where the treatment, known as palovarotene, has been approved for use. Participants will either be treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information) or untreated with palovarotene.
The main aim of this registry study will be to collect and assess real-world safety data on children and adult participants with FOP treated with palovarotene.
This registry study will also describe the effectiveness of palovarotene in exposed participants, including the effect on everyday activities and physical performance.
In addition, this registry study aims to descriptively compare key safety outcomes (i.e. flare-up episodes, growth outcomes, and bone fractures) between participants exposed and unexposed to palovarotene.
Studieoversikt
Status
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Ipsen Clinical Study Enquiries
- Telefonnummer: see email
- E-post: clinical.trials@ipsen.com
Studiesteder
-
-
-
Edmonton, Canada
- Rekruttering
- Edmonton Clinic Health Academy (ECHA)- University of Alberta
-
Oakville, Canada
- Aktiv, ikke rekrutterende
- Bone Research and Education Centre
-
Toronto, Canada
- Rekruttering
- University Health Network (UHN) - Toronto General
-
-
-
-
California
-
San Francisco, California, Forente stater, 94103
- Rekruttering
- The Regents of the University of California
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Rekruttering
- The Trustees of the University of Pennsylvania, Office of Clinical Research-Legal Services, Perelman School of Medicine
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Adults and children with FOP who have been prescribed palovarotene, as per local label, by their treating physician for which informed consent has been obtained and maintained. Participants cannot be included if they are currently participating in a palovarotene clinical trial or an interventional clinical trial for FOP or if they have any contraindication for palovarotene (except for pregnant women who have previously received and discontinued palovarotene at any time during the pregnancy and who will be included for safety follow-up).
Beskrivelse
Inclusion Criteria :
- Adult or child with FOP who have been prescribed palovarotene (prior to and independently of the decision to enroll the patient in this registry study and as per local label) by their treating physician according to the locally approved product information;
- Signed informed consent as per local regulations must be obtained and maintained. Consent/assent from the participant should be obtained as appropriate before any registry study data collection are conducted. If applicable, parents or legally authorized representatives must give signed informed consent.
Exclusion Criteria :
- Currently participating in a palovarotene clinical trial;
- Currently participating in any interventional clinical trial for FOP;
- Have any contraindication to palovarotene as per the locally approved label (except for pregnant women who have previously received and discontinued palovarotene at any time during the pregnancy and who will be included for safety follow-up).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: OTHER
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Exposed Cohort
Participants treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information) |
|
Unexposed Cohort
Participants untreated with palovarotene |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), whether or not they are considered as related to palovarotene
Tidsramme: From Baseline up to 30 days after the last palovarotene dose.
|
Adverse events will be coded according to MedDRA and will be classified by Preferred Term (PT) and system organ class (SOC). |
From Baseline up to 30 days after the last palovarotene dose.
|
|
Percentage of Participants With Serious and Non-serious treatment-related TEAEs
Tidsramme: From Baseline up to 30 days after the last palovarotene dose.
|
Adverse events will be coded according to MedDRA and will be classified by PT and SOC. |
From Baseline up to 30 days after the last palovarotene dose.
|
|
Percentage of Participants With all serious TEAEs, whether or not they are considered as related to the palovarotene
Tidsramme: From Baseline up to 30 days after the last palovarotene dose.
|
Adverse events will be coded according to MedDRA and will be classified by PT and SOC. |
From Baseline up to 30 days after the last palovarotene dose.
|
|
Percentage of Participants With nonserious TEAEs whether or not they are considered as related to the palovarotene.
Tidsramme: From Baseline up to 30 days after the last palovarotene dose.
|
Adverse events will be coded according to MedDRA and will be classified by PT and SOC. |
From Baseline up to 30 days after the last palovarotene dose.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Antall oppblussinger
Tidsramme: Fra 12 måneder før inkludering Baseline opp til elleve år.
|
Fra 12 måneder før inkludering Baseline opp til elleve år.
|
|
|
Antall lokasjoner påvirket per deltaker
Tidsramme: Fra baseline og årlig opp til elleve år.
|
Fra baseline og årlig opp til elleve år.
|
|
|
Evolusjon av påvirket beliggenhet (hvor mange ganger et sted påvirkes) per sted
Tidsramme: Fra baseline og årlig opp til elleve år.
|
Fra baseline og årlig opp til elleve år.
|
|
|
Gjennomsnittlig dose/år med palovaroten for deltakere med FOP utsatt og ueksponert for palovaroten for kronisk behandling
Tidsramme: Fra baseline og hvert halvår opp til elleve år.
|
Fra baseline og hvert halvår opp til elleve år.
|
|
|
Gjennomsnittlig dose/syklus av palovaroten for deltakere med FOP utsatt og ueksponert for palovaroten for oppblussing
Tidsramme: Fra baseline og hvert halvår opp til elleve år.
|
Fra baseline og hvert halvår opp til elleve år.
|
|
|
Change from Baseline in Cumulative Analogue Joint Involvement Scale (CAJIS) total score
Tidsramme: From Baseline and every six months up to eleven years.
|
The CAJIS is an objective measure of joint movement completed by the Investigator to document total joint involvement. The CAJIS total score is calculated as the sum of the scores of all joints/regions and ranges from 0 (no involvement) to 30 (maximally involved). |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in use of assistive devices
Tidsramme: From Baseline and every six months up to eleven years.
|
Assistive devices is a questionnaire to assess the assistive devices used by particpants and adaptations for their daily living. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in percent of worst score for Fibrodysplasia Ossificans Progressiva-Physical Function Questionnaire (FOP-PFQ) total score
Tidsramme: From Baseline and every six months up to eleven years.
|
Fibrodysplasia Ossificans Progressiva-Physical Function Questionnaire (FOP-PFQ) consists of questions which are scored on a scale of 1 to 5, lower scores indicating that the participant has more difficulties. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in observed and percent predicted Forced Vital Capacity (FVC)
Tidsramme: From Baseline and every six months up to eleven years.
|
The lung function parameters of observed FVC (liters) and percent predicted FVC are obtained by spirometry. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in observed and percent predicted Forced Expiratory Volume in one second (FEV1)
Tidsramme: From Baseline and every six months up to eleven years.
|
The lung function parameters of observed FEV1 (liters) and percent predicted FEV1 are obtained by spirometry. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in absolute and percent predicted FEV1/FVC ratio
Tidsramme: From Baseline and every six months up to eleven years.
|
The lung function parameters of the absolute and percent predicted FEV1/FVC ratio are obtained by spirometry. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in observed and percent predicted Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)
Tidsramme: From Baseline and every six months up to eleven years.
|
The lung function parameters of observed (traditional unit of mL/min/mmHg or SI unit of mmol/min/kPa) and percent predicted DLCO is obtained by the DLCO test. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) physical and mental function (mean global physical and mental health score converted into T-scores) for participants ≥15 years old
Tidsramme: From Baseline and every six months up to eleven years.
|
PROMIS Global Health Scale for the adult version, the global physical health and global mental health scores will be calculated as follows:
|
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in PROMIS overall quality of life (QoL) (mean total score converted into T-scores) for participants <15 years old
Tidsramme: From Baseline and every six months up to eleven years.
|
PROMIS Global Health Scale for the paediatric version, the total score will be calculated as the sum of scores from the first 7 questions and will range from 7 (worse health) to 35 (better health). If more than 3 questions contributing to the total score are missing, the total score will not be calculated. It will be considered as missing. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in annualized number of Investigator-reported flare-ups by body location and overall
Tidsramme: From Baseline and every six months up to eleven years.
|
The annualized number of flare-ups will be derived from the number of flare-ups the participant experienced since last visit. |
From Baseline and every six months up to eleven years.
|
|
Number of flare-up outcomes
Tidsramme: From Baseline and every six months up to eleven years.
|
Number of flare-up outcomes as measured by new bone growth, restricted movement at each visit will be reported. |
From Baseline and every six months up to eleven years.
|
|
Flare-up Duration
Tidsramme: From Baseline and every six months up to eleven years.
|
Flare-up duration will be assessed by body location and overall, at each visit. |
From Baseline and every six months up to eleven years.
|
|
Movement mobility change
Tidsramme: From Baseline and annually up to eleven years.
|
Assessed by key body location: better movement/the same movement/slightly worse movement/moderately worse movement/severely worse movement) |
From Baseline and annually up to eleven years.
|
|
Movement mobility outcomes: Percentage of participants with new bone growth overall and by flare-up status
Tidsramme: From Baseline and every six months up to eleven years.
|
The number of extra bone growths, location of the extra bone growth, whether it was preceded by injury, illness, vaccination and/or other events, whether it was preceded by pain, soft tissue swelling, decreased range of motion, stiffness, redness, or warmth, extra bone growth start and stop date and whether it is ongoing, will be collected. |
From Baseline and every six months up to eleven years.
|
|
Percentage of participants with any fractures overall
Tidsramme: From baseline up to 30 days after the last palovarotene dose.
|
Assessed by radiological imaging and clinical examination. |
From baseline up to 30 days after the last palovarotene dose.
|
|
Change from Baseline in annualized number of fractures by body location and overall
Tidsramme: From baseline up to 30 days after the last palovarotene dose.
|
Assessed by radiological imaging and clinical examination. |
From baseline up to 30 days after the last palovarotene dose.
|
|
Incidence of pregnancy
Tidsramme: From Baseline and every month up to 30 days after the last palovarotene dose.
|
A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy and the health status of the baby will be verified |
From Baseline and every month up to 30 days after the last palovarotene dose.
|
|
Description of pregnancy characteristics and outcomes
Tidsramme: From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy. |
From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
|
Description of pregnancy related Adverse Events (AEs)
Tidsramme: From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy. |
From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
|
Description of birth and developmental outcomes through the first year after birth
Tidsramme: From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy. |
From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
|
Description of birth and developmental outcomes through the first year after birth
Tidsramme: From Baseline and every six months up to eleven years.
|
Linear height and knee height velocity will be derived for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in height z-score
Tidsramme: From Baseline and every six months up to eleven years.
|
Linear height z-score will be derived for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached. |
From Baseline and every six months up to eleven years.
|
|
Mean difference between chronological age and bone age
Tidsramme: From Baseline and every six months up to eleven years.
|
Bone age (assessment as per the SmPC/PI) and chronological age will be collected for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached. |
From Baseline and every six months up to eleven years.
|
|
Frequency of premature physeal closure (PPC) overall
Tidsramme: From baseline up to 30 days after the last palovarotene dose
|
Epiphyseal status ("open" or "closed") (assessment as per the SmPC/PI) will be collected for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached. |
From baseline up to 30 days after the last palovarotene dose
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Ipsen Medical, Director, Ipsen
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CLIN-60120-453
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
IPD-delingstidsramme
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Tilgangskriterier for IPD-deling
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .